Clinical outcomes and health care costs combining metformin with sitagliptin or sulphonylureas or thiazolidinediones in uncontrolled type 2 diabetes patients

References

• International Diabetes Federation [webpage on the Internet]Diabetes atlas6th editionBrussels, BelgiumInternational Diabetes Federation2009 Available from: http://www.diabetesatlas.org/content/diabetesAccessed March 29, 2013
   Google Scholar
• GrundySMBenjaminIJBurkeGLDiabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart AssociationCirculation1999100101134114610477542
   PubMed Web of Science ®Google Scholar
• SobelBESchneiderDJCardiovascular complications in diabetes mellitusCurr Opin Pharmacol20055214314815780822
   PubMed Web of Science ®Google Scholar
• National Diabetes Information Clearinghouse [webpage on the Internet]National diabetes statistics2011 Available from:http://diabetes.niddk.nih.gov/statistics/index.aspxAccessed March 29, 2013
   Google Scholar
• LauroRNicolucciAPublic Health and Health Policy: An Informed Health Policy on Chronic DiseasesScientific EditorConsorzio Mario Negri Sud2011
   Google Scholar
• NathanDMBuseJBDavidsonMBAmerican Diabetes AssociationEuropean Association for the Study of DiabetesMedical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of DiabetesDiabetologia2009521173018941734
   PubMed Web of Science ®Google Scholar
• American Diabetes AssociationStandard of medical care in diabetes – 2012Diabetes Care201235Suppl 1S11S1322187469
   PubMed Web of Science ®Google Scholar
• FreemanJSManaging hyperglycemia in patients with type 2 diabetes mellitus: rationale for the use of dipeptidyl peptidase-4 inhibitors in combination with other oral antidiabetic drugsJ Am Osteopath Assoc2010110952853720876838
   PubMedGoogle Scholar
• Degli EspostiLSaragoniSBudaSSturaniADegli EspostiEGlycemic control and diabetes-related health care costs in type 2 diabetes; retrospective analysis based on clinical and administrative databasesClinicoecon Outcomes Res2013519320123696709
   PubMedGoogle Scholar
• Di BariMBalziDRobertsATPrognostic stratification of older persons based on simple administrative data: development and validation of the “Silver Code,” to be used in emergency department triageJ Gerontol A Biol Sci Med Sci201065215916419349591
   PubMed Web of Science ®Google Scholar
• Ministero del lavoro, della Salute e delle Politiche SocialiRapporto annuale sulle attività di ricovero ospedaliero [Annual report on the activities of hospitalization]2009 Available from: http://www.salute.gov.it/imgs/C_17_pubblicazioni_1491_allegato.pdfAccessed December 22, 2013 Italian
   Google Scholar
• Centers for Disease Control and Prevention [homepage on the Internet]International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) [updated 2010 Sep 21; reviewed 2010 Sep 21; cited 2010 Nov 23]. Available from: http://www.cdc.gov/nchs/icd/icd9cm.htmAccessed May, 13, 2013
   Google Scholar
• CharlsonMEPompeiPAlesKLMacKenzieCRA new method of classifying prognostic comorbidity in longitudinal studies: development and validationJ Chronic Dis19874053733833558716
   PubMedGoogle Scholar
• American Diabetes AssociationDiagnosis and classification of diabetes mellitusDiabetes Care201033Suppl 1S62S6920042775
   PubMed Web of Science ®Google Scholar
• FarmerKCMethods for measuring and monitoring medication regimen adherence in clinical trials and clinical practiceClin Ther199921610741090 discussion 107310440628
   PubMed Web of Science ®Google Scholar
• CohenHWShmuklerCUllmanRRiveraCMWalkerEAMeasurements of medication adherence in diabetic patients with poorly controlled HbA(1c)Diabet Med201027221021620546266
   PubMed Web of Science ®Google Scholar
• L’Informatore farmaceutico italiano [The Italian pharmaceutical informer]ItalyElsevier2012 Available from: http://www.informatorefarmaceutico.it/Accessed April 11, 2013 Italian
   Google Scholar
• GaryTLCrumRMCooper-PatrickLFordDBrancatiFLDepressive symptoms and metabolic control in African-Americans with type 2 diabetesDiabetes Care2000231232910857963
   PubMed Web of Science ®Google Scholar
• SkaerTLSclarDAMarkowskiDJWonJKEffect of value-added utilities on prescription refill compliance and Medicaid health care expenditures – a study of patients with non-insulin-dependent diabetes mellitusJ Clin Pharm Ther19931842952998227238
   PubMed Web of Science ®Google Scholar
• BarberJThompsonSMultiple regression of cost data: use of generalised linear modelsJ Health Serv Res Policy20049419720415509405
   PubMedGoogle Scholar
• InzucchiSEBergenstalRMBuseJBAmerican Diabetes Association (ADA)European Association for the Study of Diabetes (EASD)Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)Diabetes Care20123561364137922517736
   PubMed Web of Science ®Google Scholar
• McIntoshBCameronCSinghSRYuCAhujaTWeltonNJDahlMSecond-line therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a systematic review and mixed-treatment comparison meta-analysisOpen Med201151e35e4822046219
   PubMedGoogle Scholar
• EspositoKCerielloAGiuglianoDDoes personalized diabetology overcome clinical uncertainty and therapeutic inertia in type 2 diabetes?Endocrine201344234334523479044
   PubMed Web of Science ®Google Scholar
• HuxJEIvisFFlintoftVBicaADiabetes in Ontario: determination of prevalence and incidence using a validated administrative data algorithmDiabetes Care200225351251611874939
   PubMed Web of Science ®Google Scholar
• SolbergLIEngebretsonKISperl-HillenJMHroscikoskiMCO’ConnorPJAre claims data accurate enough to identify patients for performance measures or quality improvement? The case of diabetes, heart disease, and depressionAm J Med Qual200621423824516849780
   PubMed Web of Science ®Google Scholar
• BrownJBNicholsGAGlauberHSCase-control study of 10 years of comprehensive diabetes careWest J Med20001722859010693367
   PubMedGoogle Scholar
• McIntoshBCameronCSinghSRSecond-line therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a systematic review and mixed-treatment comparison meta-analysisOpen Med201151e35e4822046219
   PubMedGoogle Scholar
• PhungOJScholleJMTalwarMColemanCIEffect of noninsulin antidiabetic drugs added to metformin therapy on glycemic control, weight gain, and hypoglycemia in type 2 diabetesJAMA2010303141410141820388897
   PubMed Web of Science ®Google Scholar
• Sicras MainarARoldán SuárezCFont RamosBNavarro ArtiedaRIbáñez NollaJClinical and economical consequences of the combination of metformin with dipeptidyl peptidase inhibitors in type 2 diabetes patientsRev Clin Esp2013213837738423870706
   PubMed Web of Science ®Google Scholar
• JinJSklarGEMin SenOh VChuen LiSFactors affecting therapeutic compliance: A review from the patient’s perspectiveTher Clin Risk Manag20084126928618728716
   PubMedGoogle Scholar
• BaileyCJKodackMPatient adherence to medication requirements for therapy of type 2 diabetesInt J Clin Pract201165331432221314869
   PubMed Web of Science ®Google Scholar
• ZhangYMcCoyRGMasonJESmithSAShahNDDentonBTSecond-line agents for glycemic control for type 2 diabetes: are newer agents better?Diabetes Care201453751338134524574345
   PubMed Web of Science ®Google Scholar
• WaughNCumminsERoylePNewer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluationHealth Technol Assess201014361248
   Web of Science ®Google Scholar
• SchwarzBGouveiaMChenJCost-effectiveness of sitagliptin-based treatment regimens in European patients with type 2 diabetes and haemoglobin A1c above target on metformin monotherapyDiabetes Obes Metab200810Suppl 1435518435673
   PubMed Web of Science ®Google Scholar
• GranströmOBergenheimKMcEwanPSennfältKHenrikssonMCost-effectiveness of saxagliptin (Onglyza®) in type 2 diabetes in SwedenPrim Care Diabetes20126212713622001114
   PubMed Web of Science ®Google Scholar
• SinhaARajanMHoergerTPogachLCosts and consequences associated with newer medications for glycemic control in type 2 diabetesDiabetes Care201033469570020056950
   PubMed Web of Science ®Google Scholar
• KlarenbachSCameronCSinghSUrECost-effectiveness of second-line antihyperglycemic therapy in patients with type 2 diabetes mellitus inadequately controlled on metforminCMAJ201118316E1213E122021969406
   PubMed Web of Science ®Google Scholar
• ReidTChoosing GLP-1 receptor agonists or DPP-4 inhibitors: weighing the clinical trial evidenceClinical Diabetes2012301312
   Google Scholar